MHRA Admits UK Medtechs Exposed To Risks As It Consults On Brexit No-Deal Impact
Executive Summary
The UK Medicines and Healthcare products Regulatory Agency is now consulting, in detail, on what a no-deal Brexit could look like and how it would impact manufacturers and the MHRA itself. Companies have less than four weeks to respond.